Close
Novotech
Jabsco PureFlo 21 Single Use

Why are decentralised clinical trials the future of the industry

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Smarter Trial Design Improves Drug Development Speed

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

Data Driven Decisions Improve Drug Development Outcomes

Integrating comprehensive analytics and real-world data into clinical planning allows pharmaceutical companies to optimize trial design and significantly improve patient outcomes.

Efficient Early Strategies Enable Faster Clinical Progress

Implementing optimized early-stage frameworks and enhancing trial readiness allows pharmaceutical sponsors to accelerate clinical timelines and maintain high R&D efficiency.
- Advertisement -

Decentralized clinical trials (DCTs) can be considered to be the future of the industry due to the benefits they provide to drug developers and patients and their growing popularity. These benefits include ease for patients to participate in trials as they can do so remotely from home, as well as reducing the cost of research as less staff and resources are required as fewer patients visit trial sites.

Traditional clinical trials are often limited to studying diseases and conditions that are common enough to have a large number of patients available to participate. However DCTs can be used to study a wider range of diseases and conditions because they can reach a larger pool of patients, with more emerging rare diseases and small patient pools, the demand for DCTs will increase.

DCTs can help to accelerate the development of new treatments. Traditional clinical trials can take many years to complete. This is because they require a long time to recruit patients, collect data, and analyze the data. DCTs can help to accelerate the development of new treatments by reducing the time it takes to recruit patients and collect data.

DCTs can also help to improve patient recruitment and retention as studies have shown that patients are more likely to participate in DCTs than traditional clinical trials due to their flexibility and convenience.

Finally, DCTs can also help to improve patient safety. By using technology to collect data remotely, DCTs can provide researchers with real-time data on patient health. This data can be used to identify and address potential safety concerns as soon as possible.

For all of these reasons DCTs offer a number of advantages over traditional clinical trials. They have the potential be more efficient, effective, affordable, and patient-centred. Because of these reasons it is responsible to consider DCTs the future of clinical research as their limitations and the regulatory concerns will be addressed due to their growing popularity.

About Author

Claude Price, Vice President and Head of Clinical Data Management at Quanticate

 

 

 

 

Quanticate
Company Logo

Latest stories

Related stories

Smarter Trial Design Improves Drug Development Speed

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

Data Driven Decisions Improve Drug Development Outcomes

Integrating comprehensive analytics and real-world data into clinical planning allows pharmaceutical companies to optimize trial design and significantly improve patient outcomes.

Efficient Early Strategies Enable Faster Clinical Progress

Implementing optimized early-stage frameworks and enhancing trial readiness allows pharmaceutical sponsors to accelerate clinical timelines and maintain high R&D efficiency.

Early Insights Reduce Risk in Drug Development Programs

Leveraging early-stage data and translational research allows pharmaceutical companies to mitigate drug development risk and implement adaptive strategies for higher success.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »